Euglena Dirección

Dirección controles de criterios 2/4

El CEO de Euglena's es Tomohiro Wakahara, nombrado en Jan 2021, tiene una permanencia de 3.42 años. posee directamente un 0.013% de las acciones de la empresa, con un valor de ¥9.61M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 5.5 años, respectivamente.

Información clave

Tomohiro Wakahara

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.4yrs
Participación del CEO	0.01%
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Tomohiro Wakahara

3.4yrs

Permanencia

Mr. Tomohiro Wakahara is Representative Executive Officer at Euglena Co., Ltd. since 2018 and serves as Co-Chief Executive Officer since 2024. He serves as Director at Euglena Co., Ltd.He served as its M...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Tomohiro Wakahara	Representative Executive Officer	3.4yrs	sin datos	0.013% ¥ 9.3m
Hiroko Uemura	Representative Executive Officer	less than a year	sin datos	0.0029% ¥ 2.1m
Mitsuru Izumo	Founder	no data	sin datos	9.03% ¥ 6.4b
Kengo Suzuki	Executive Officer & CTO	2.4yrs	sin datos	0.87% ¥ 615.2m
Daisuke Susa	Executive Officer & Chief Administrative Officer	no data	sin datos	sin datos
Satake Yukoh	Executive Officer & Chief Legal Officer	less than a year	sin datos	sin datos
Korehiro Odate	Executive Officer & Head of Energy Company	6.4yrs	sin datos	sin datos
Shoko Takahashi	Executive Officer & Bioinformatics Business Head	6.4yrs	sin datos	sin datos
Yasuhiro Fukutomi	Special Officer & CSO	2.4yrs	sin datos	sin datos
Yukihiro Maru	Professional Officer & CRO	2.4yrs	sin datos	sin datos
Yuichi Hoshino	Executive Officer & CIO	2.4yrs	sin datos	sin datos
Midori Watabe	Chief Future Officer	2.4yrs	sin datos	sin datos

2.4yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2931 se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tomohiro Wakahara	Representative Executive Officer	no data	sin datos	0.013% ¥ 9.3m
Hiroko Uemura	Representative Executive Officer	less than a year	sin datos	0.0029% ¥ 2.1m
Mitsuru Izumo	Founder	18.8yrs	sin datos	9.03% ¥ 6.4b
Etsuko Okajima	Director	6.4yrs	sin datos	0.021% ¥ 15.1m
Makoto Shimizu	Independent Outside Director	8.5yrs	sin datos	sin datos
Mirai Murakami	Independent Outside Director	3.5yrs	sin datos	sin datos
Masahiro Kotosaka	Independent Outside Director	5.5yrs	sin datos	0.019% ¥ 13.5m
Aiko Mochizuki	Independent Outside Director	3.5yrs	sin datos	sin datos

5.5yrs

Permanencia media

44.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2931 se considera experimentada (5.5 años de antigüedad promedio).

Euglena Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024

Insufficient new directors

Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023

Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022

Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020

Recent updates

Euglena Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2024

First quarter 2024 earnings released: EPS: JP¥1.48 (vs JP¥1.45 loss in 1Q 2023)

Euglena Co., Ltd. to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Euglena Co., Ltd., Annual General Meeting, Mar 19, 2024

Full year 2023 earnings released: JP¥22.75 loss per share (vs JP¥23.83 loss in FY 2022)

Zenhoren Co.,Ltd. (TSE:5845) agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. (TSE:2931) for ¥360 million.

Euglena Co., Ltd. (TSE:2931) agreed to acquire Saticine Medical Co., Ltd.

Insufficient new directors

Euglena Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: JP¥2.98 loss per share (vs JP¥15.91 loss in 3Q 2022)

Euglena Co., Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Second quarter 2023 earnings released

Euglena Co., Ltd. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings released

Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)

Price target increased by 11% to JP¥1,000

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023

Euglena Co., Ltd., Annual General Meeting, Mar 24, 2023

Full year 2022 earnings released: JP¥23.83 loss per share (vs JP¥44.51 loss in FY 2021)

Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc.

Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd.

Euglena Co., Ltd. to Report Fiscal Year 2022 Results on Feb 13, 2023

Euglena Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. to Report Q2, 2022 Results on Aug 10, 2022

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings released: JP¥39.26 loss per share (vs JP¥17.15 loss in FY 2020)

Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Euglena Co., Ltd., Annual General Meeting, Mar 26, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Euglena Co., Ltd. Provides Earnings Guidance for the Period from October 1, 2020 to December 31, 2021

Euglena Co., Ltd. Provides Consolidated Sales Guidance for the Full Year Ending September 30, 2021

Second quarter 2021 earnings released: EPS JP¥1.75 (vs JP¥1.17 in 2Q 2020)

Euglena Co., Ltd., Chevron Lummus Global and Applied Research Associates, Inc. Announce Successful Production of Renewable Jet Fuel

New 90-day high: JP¥1,264

Euglena Co., Ltd. to Report Q2, 2021 Results on May 14, 2021

First quarter 2021 earnings released: JP¥3.87 loss per share (vs JP¥2.71 loss in 1Q 2020)

New 90-day high: JP¥909

Euglena Co., Ltd. (TSE:2931) entered into an agreement to acquire Liguna, K.K. from Noriko Minamizawa and Takeshi Matsumoto.

Euglena Co., Ltd. to Report Q1, 2021 Results on Feb 15, 2021

Full year 2020 earnings released: JP¥16.00 loss per share

New 90-day low: JP¥774

The fund managed by Advantage Partners, Inc., Euglena Co., Ltd. (TSE:2931) and Tokyo Century Corporation (TSE:8439) agreed to acquire Q' Sai Co., Ltd. from Coca-Cola Bottlers Japan Holdings Inc. (TSE:2579).

New 90-day low: JP¥797

Euglena Co., Ltd., Annual General Meeting, Dec 18, 2020

Euglena Co., Ltd. to Report Fiscal Year 2020 Results on Nov 13, 2020

Euglena Co., Ltd. (TSE:2931) cancelled the acquisition of MEJ Inc. from Toru Koga and others.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad